Was haltet ihr von Caliper Tech.? WKN 931431 - 500 Beiträge pro Seite

[tradi]

Hallo an alle,

Im GBI-Brief 16/2000 steht ja nur gutes über Caliper Tech. Was haltet Ihr von diesem Wert? Soll man ein paar Aktien kaufen oder nicht?

Danke im Voraus...

bis dann....

tradi

[batschkapp]

Der abgebildete Chart seit Mai schaut vielversprechend aus (Kurs verdreifacht.Aktuell um die 65€.). Bei dem Höchststand von USD 202 im April sollte man sich wirklich ein paar ins Depot legen.

[batschkapp]

Für alle, die Global Biotech Investing nicht lesen können ganz kurz:
"Die gesellschaft ermöglicht Gen- und Proteinanalysenmit einem Minimum an technischer Ausrüstung. (...PC-grosse Calyper-Boxen...) Dem Unternehmen brachte die im Vorjahr bekanntgegebene Kooperation mit Millenium Pharma den Durchbruch. ... Bereits im nächsten Jahr wird das errreichen der Gewinnschwelle und ein kleiner Nettogewinn von USD 0,9Mio. erwartet, der sich im Folgejahr auf USD 15 Mio. vervielfachen soll ...12 Monate vor erreichen der Gewinnzone noch mehr als USD 73 Mio. Cash auf der Bank. ..."
Grüßung
batschkapp

[tradi]

Hallo,

was haltet ihr denn von caliper tech?

Bitte um euere Meinungen..

danke

bis dann

tradi

[tradi]

Hallo,

hat keiner eine Meinung zu Caliper?? :-))

bis dann.....

tradi

[MoneyMoneyMoney]

Nicht unbeträchtliches Risiko, aber große Chance !!!
Habe mir grad ein paar zu 62€ ins Depot gelegt !!!

MMM

[Gatsby2]

Caliper wird m.E. ein ganz grosser Winner. Nachdem die Anwaelte im Ramsey-Prozess gegen Zahlung von $12 Mio aus dem
Ramsey-Patent-Prozess ausgeschieden sind, hat CALP gestern einen weiteren Prozess gegen ACLA gewonnen:

Friday October 27, 11:07 pm Eastern Time

Press Release

SOURCE: Caliper Technologies Corp.

Caliper Wins Trade Secret Theft Case Against Aclara:
Jury Awards Caliper More Than $52 Million in
Damages

MOUNTAIN VIEW, Calif., Oct. 27 /PRNewswire/ -- Caliper Technologies Corp. (Nasdaq:
CALP - news) announced that a jury has ruled in favor of Caliper in its lawsuit charging trade secret misappropriation by Aclara
BioSciences (Nasdaq: ACLA - news). The jury returned a total award in the amount of $52,568,000. This award includes
$21,135,000 in damages for misappropriation of trade secrets; $26,450,000 for unjust enrichment of Aclara; and $4,983,000 in
damages for conversion. Caliper`s claims for an injunction on the issue of misuse of trade secrets and other equitable remedies will
be determined by the court at a later date.

``We are deeply gratified by the court`s decision and want to express our sincere appreciation to the jury for their efforts in this
complicated case,`` said Dan Kisner, M.D., Caliper`s President and Chief Executive Officer. ``We feel that the outcome of this
trial is not only a victory for Caliper and our stockholders, but for the legal system as well. Now that this issue is behind us, we
look forward to focusing our efforts on continuing to strengthen our leadership in microfluidic technology and lab-on-a-chip
products, delivering valuable products to our customers and building long-term stockholder value.``

This verdict in this case is separate from the ongoing litigation brought by Caliper for infringement of the Ramsey patents, or the
litigation brought by Aclara against Caliper for infringement of Aclara`s `015 patent. A Markman hearing to construe the claims of
the Ramsey patents is scheduled for November 20, 2000, with a likely trial date in mid 2001. A Markman hearing to construe the
claims of the `015 patent was held in June 2000. The court`s ruling accepted Caliper`s interpretation of key terms in the patent
claims. A summary judgement hearing on this case was held on Friday, October 27, 2000, and a decision from the judge is
expected shortly. If the case is not resolved on summary judgement, the trial is scheduled to take place in December 2000.

Caliper Technologies Corp. is a leader in lab-on-a-chip technology. Caliper designs, manufactures, and commercializes LabChip®
devices and systems that enable experiments that ordinarily require laboratories full of equipment and people to be conducted on a
chip small enough to fit in the palm of a child`s hand. The chip contains a network of microscopic channels through which fluids
and chemicals are moved in order to perform the experiment. The LabChip® systems are designed to streamline and accelerate
laboratory experimentation and have potential applicability in a broad range of industries including pharmaceuticals, agriculture,
chemicals and diagnostics. Caliper has established multiple strategic and commercial alliances and has built a leading intellectual
property estate in microfluidic technology.

The foregoing discussion of the jury`s decision in Caliper`s trade secret misappropriation case against Aclara involves risks and
uncertainty, including the risks: that Aclara may appeal the verdict, and, if they are successful, the verdict could be overturned;
that an appeal process could be lengthy and require additional expense; that the damages award may be reduced by the judge; and
that the final damages award will be reduced by the amount equal to the settlement received by Caliper in a related case. The
statements regarding the timing of future legal proceedings are forward-looking statements that involve risks and uncertainties,
including the risks that these proceedings may be postponed for a variety of reasons, including the filing of additional motions by
Caliper or Aclara. These and other risks related to Caliper are detailed in Caliper`s Annual Report on Form 10-K filed with the
SEC dated March 24, 2000.

NOTE: LabChip is a registered trademark of Caliper Technologies Corp.

SOURCE: Caliper Technologies Corp.

[Mandfredo]

Kann mir das mal jemand übersetzen

[FLOTSAM_AND_JETSAM_US]

wie bereits von gatsby2 angeführt hat CALP einen weitern prozeß gegen
acla gewonnen, wobei es um firmengeheimnisse ging.
die jury hat CALP $52 Million zugesprochen.
dabei ist nicht nur die zahlung entscheident, sondern es wird auch die technologieführerschaft von calp im laborchipsegment gefestigt

[Gatsby2]

Sorry, aber es geht schon wieder in Englisch weiter. Darum die Zusammenfassung kurz vorweg: Im ersten post
ist die Nachricht, dass Caliper einen weiteren, wichtigen Prozeß gegen Aclara zu einem guten Teil gewonnen hat.
Im zweiten post folgt dann die Sensation: Zwar sind die $12 mio von den Anwälten als außerordentlichen Ein-
nahmen mit eingebucht, aber dennoch fast unglaublich: CALP schreibt erstmals Gewinn.

Tuesday October 31, 4:02 pm Eastern Time

Press Release

SOURCE: Caliper Technologies Corp.

Caliper Granted Partial Summary Judgment in Patent
Infringement Case

MOUNTAIN VIEW, Calif., Oct. 31 /PRNewswire/ -- Caliper Technologies Corp. (Nasdaq:
CALP - news) today announced that the U.S. District Court for the Northern District of California granted Caliper`s motion for
summary judgement that its LabChip® products do not literally infringe the claims of U.S. Patent #5,750,015 (the `015 patent)
which was asserted by Aclara BioSciences (Nasdaq: ACLA - news) against Caliper. The Court ruled as a matter of law that
Caliper`s LabChip® devices do not literally infringe the claims of the `015 patent on two separate grounds. First, the Court held
that the trenches recited in the claims of the `015 patent are different than the sealed channels in Caliper`s LabChip® devices.
Second, the Court held that Caliper`s LabChip® devices do not employ the same electrode placement as required by the claims in
the `015 patent.

The Court declined to grant summary judgment on infringement under the doctrine of equivalents. The doctrine of equivalents is
considered when literal infringement is lacking, and can be employed under certain circumstances to expand the scope of claims to
cover devices that are only insubstantially different from the literal meaning of the claims. Caliper believes that its devices do not
meet the rigorous standard for application of this doctrine, but the Court concluded that this issue presented factual questions that
would need to be considered at trial. The Court also declined to grant summary judgment that the `015 patent is invalid, concluding
that Caliper`s invalidity arguments also presented factual issues requiring a trial on the merits. The Court is still considering
Caliper`s motion for summary judgment of unenforceability of the `015 patent based on inequitable conduct.

``The Court has, once again, ruled in favor of Caliper in this summary judgement,`` said Dan Kisner, M.D., President and Chief
Executive Officer. ``In essence, the Court has decided that Caliper`s LabChip® devices are different from what is claimed in the
`015 patent. We are not surprised that the Court has chosen to leave the question of doctrine of equivalents for a trial, but we
believe that the differences between Caliper`s products and the claims of the `015 patent are quite substantial, and we look
forward to establishing these differences at trial. We are also pleased to have the opportunity to prove that the `015 patent is both
invalid and unenforceable. Based upon our recent experiences, we have great confidence in the legal system to provide an
outcome that is favorable to Caliper.``

Caliper Technologies Corp. is a leader in lab-on-a-chip technology. Caliper designs, manufactures, and commercializes LabChip®
devices and systems that enable experiments that ordinarily require laboratories full of equipment and people to be conducted on a
chip small enough to fit in the palm of a child`s hand. The chip contains a network of microscopic channels through which fluids
and chemicals are moved in order to perform the experiment. The LabChip® systems are designed to streamline and accelerate
laboratory experimentation and have potential applicability in a broad range of industries including pharmaceuticals, agriculture,
chemicals and diagnostics. Caliper has established multiple strategic and commercial alliances and has built a leading intellectual
property estate in microfluidic technology.

Note: This news release contains forward-looking statements relating to Caliper`s beliefs regarding the strength of its position on
the issues of invalidity and unenforceability of the `015 patent, and the application of the doctrine of equivalence. The ultimate
outcome at trial is subject to risks and uncertainties, including that a jury will view the facts differently from Caliper, and that for
other reasons litigation is inherently uncertain. These and other risks related to Caliper are detailed in Caliper`s Annual Report on
Form 10-K filed with the SEC dated March 24, 2000.

NOTE: LabChip is a registered trademark of Caliper Technologies Corp.

SOURCE: Caliper Technologies Corp.

[Gatsby2]

Die aktuellen Kursziele liegen uebrigens zwischen $ 133,-- und $ 200,--.

Tuesday October 31, 4:01 pm Eastern Time

Press Release

SOURCE: Caliper Technologies Corp.

Caliper Announces Third Quarter 2000 Financial
Results

Earnings of $0.25 Per Diluted Share Reported As a Result of
Operations and Litigation Settlement

MOUNTAIN VIEW, Calif., Oct. 31 /PRNewswire/ -- Caliper Technologies Corp. (Nasdaq: CALP - news) today announced its
third quarter financial results for 2000. For the quarter ended September 30, 2000, the company reported net income of $6.1 million
or $0.25 per diluted share as compared to a net loss of $3.6 million or $0.23 per diluted share for the same quarter last year.
Included in the net income for this third quarter of 2000 is $12.0 million or $0.49 per diluted share from the breach of duty and
trade secret misappropriation litigation settlement signed in September 2000. Excluding this litigation settlement, the third quarter of
2000 would have been a net loss of $5.9 million or $0.27 per diluted share. For the first nine months of 2000, the company reported
a net loss of $7.5 million or $0.35 per diluted share as compared to a net loss of $8.1 million or $0.53 per diluted share for the same
period in 1999. Included in the net loss for the nine months ending September 30, 2000, in addition to the litigation settlement noted
above, is a cumulative adjustment of $2.3 million or $0.11 per diluted share for the effect of Staff Accounting Bulletin 101 (SAB
101) on revenue recognition adopted by the company in the first quarter of the 2000 fiscal year.

Total revenues were $5.5 million for the quarter ended September 30, 2000, as compared to $3.4 million in revenues for the same
period in 1999, representing a 61% increase. This increase is attributable equally to product sales associated with the company`s
commercial collaboration with Agilent Technologies and to the company`s Technology Access Program. Operating expenses for
the third quarter of 2000 increased over operating expenses in the comparative quarter of 1999 primarily due to expanded research
and development activities, including intellectual property matters. Also contributing to expenses were the increased administrative
costs associated with being a public company. Cash and investments totaled $190.7 million at September 30, 2000 which includes
the $104.9 million in net proceeds received from a private placement of 2.3 million shares of the company`s common stock in the
quarter.

``Caliper`s positive third quarter performance exceeded our expectations for the quarter as a result of revenue growth and aided
by the $12 million cash settlement we recorded to end litigation with an attorney and a law firm in a breach of duty and trade
secret misappropriation lawsuit,`` said Jim Knighton, Caliper`s Chief Financial Officer. ``Excluding the impact of the settlement, and
despite anticipated increases in expense, due to headcount growth and legal matters, our net loss for the quarter was smaller than
expected. The overall increase in revenue was largely driven by sales of chips and instruments, indicating growing demand for
both Caliper`s LabChip® personal laboratory systems and high throughput product lines.

Continued Mr. Knighton: ``We significantly strengthened our balance sheet this quarter with the completion of a private placement
which netted $104.9 million in cash, and with the litigation settlement agreement of $12 million. Today, we have $190.7 million in
cash and investments. The cash reserves added this quarter are intended to enable the company to implement strategic initiatives
that have the potential to solidify our leadership in the lab-on- a-chip market and to expand our technical and commercial
capabilities.``

``Caliper delivered a strong performance in the third quarter especially in the important areas of new product introductions,
expansion of our customer base, and strengthening of our balance sheet,`` said Dan Kisner, M.D., Caliper`s President and Chief
Executive Officer.

Dr. Kisner added: ``In August, Caliper and Agilent introduced the Protein 200 LabChip® kit for the performance of automated
sizing and analysis of protein samples on the Agilent 2100 Bioanalyzer. The Protein 200 LabChip® kit simplifies and speeds the
analysis of a wide variety of different protein samples, and has potential utility throughout many aspects of drug discovery and
production. Agilent is currently taking orders for this new kit and plans to begin delivery later in the fourth quarter. This is the
second new application for the 2100 we introduced this year, and we believe it will have significant commercial potential. We are
encouraged by progress in sales of the Agilent 2100 Bioanalyzer and with the increased demand for LabChip® kits. We anticipate
that the introduction of additional assays in 2001, plus enhancements to the current applications menu, will expand the customer
base and drive usage of this system in laboratories and production facilities throughout the biopharmaceutical industry.

``In September, we introduced the Automated Microfluidics System 90 (AMS 90) designed to provide microarray and cloning
laboratories with a complete, integrated and automated solution for high volume nucleic acid fragment analysis. The AMS 90 was
developed directly in response to positive feedback from customers of the Agilent 2100 Bioanalyzer requesting higher throughput
and automation for the performance of large-scale electrophoretic experiments. Capitalizing on our ability to leverage existing
technology to create new products, we adapted our DNA separation and sizing chip and assay technology to a 96-well plate
format to run on our higher throughput Caliper 100 system using a sipper chip platform. We are directly marketing the AMS 90
system to customers today as a technology access program that includes instruments, chips and services. We plan to ship AMS 90
systems later in the fourth quarter, and to expand the applications menu to include protein and other nucleic acid assays in 2001.

``In the third quarter, we initiated the Applications Developer Program (ADP), designed to enable customers to purchase
LabChip® development systems and chips to create new microfluidic applications. Participation in ADP provides users with the
tools to design applications they want, for which Caliper will produce the chips. Users may be individual biopharmaceutical
companies interested in chips and systems to develop novel microfluidic applications for their own use, or vendors of proprietary
products that could become value-added resellers of Caliper`s LabChip® systems. Caliper retains patent and commercial rights to
all chips and applications. Millennium Pharmaceuticals became the first ADP customer earlier this year, and Caliper anticipates
adding additional customers in 2001. This program is the first implementation of Caliper`s distributed applications development
strategy.

``In September, Caliper hosted its second Technology Access Program (TAP) users group meeting. All four current TAP
customers stated their goal to implement full production of high throughput screening using LabChip® systems in the first half of
2001. Full production screening activates the data point pricing model for revenue generation in the TAP. Caliper is working
aggressively to finalize instrument, chip, software and assay specifications to ensure on-time delivery of systems and to support
our customers` transition, which should begin in the first quarter of 2001. The commitment of our TAP customers to implement full
production screening is an important and positive development for Caliper, and we are dedicating all necessary resources to ensure
a successful outcome.

``Our TAP continues to generate significant interest among potential biopharmaceutical customers, and we are hopeful of adding
an additional customer to the program in the fourth quarter. Our goal in this program for 2001 is to significantly increase the
number of customers using our high throughput systems and to facilitate their transition to data point pricing as quickly as possible
to drive revenue growth.

``In the third quarter, Caliper announced that SUGEN, Inc. had become a value-added screening collaboration (VASC) customer.
We completed a screen for SUGEN using the SUGEN compound library and a selected target, and delivered the data to the
customer for further analysis. We continue to see interest in the VASC program from a number of potential customers, including
large and smaller biopharmaceutical companies, and we are hopeful of adding an additional customer to this program in the fourth
quarter.

``We believe that we have compiled a long list of achievements thus far in 2000 of which we can be proud. Among these
achievements must be included several positive outcomes in our ongoing lawsuits with Aclara BioSciences. Most recently, on
Friday, October 28, 2000, we announced that a jury ruled in favor of Caliper in its lawsuit charging trade secret misappropriation
by Aclara, and awarded Caliper more than $52 million in damages. We were deeply gratified by the court`s decision and feel that
this outcome was a victory for Caliper and its stockholders. We anticipate that there will be additional legal activity, as we plan to
seek other equitable remedies before the court and Aclara has announced it plans to appeal the jury`s decision. Nevertheless, we
believe that this decision and the $12 million settlement we recently announced with the attorneys in the trade secret
misappropriation case, vindicate our position in this matter. In addition, the favorable outcome of the Markman hearing to construe
the claims of the `015 patent, held in June 2000, strengthens our position in these litigations.

``Our goals for the remainder of this year are: to continue to increase sales of the personal laboratory system; to bring additional
customers into our high throughput screening programs; to deliver instruments and chips to our TAP customers; to begin these
customers` transition to full production screening; and to advance the commercialization of our AMS 90 and ADP programs so
that they can generate revenue in 2001. Looking ahead to 2001, we are formalizing a set of product development and commercial
goals that are designed to expand further the utility, market penetration and commercial value of our LabChip® products and
enable us to meet our performance objectives. We believe that we have made significant progress in building the foundation for
delivering a high level of performance in 2001.``

Caliper Technologies Corp. is a leader in lab-on-a-chip technology. Caliper designs, manufactures, and commercializes LabChip®
devices and systems that enable experiments that ordinarily require laboratories full of equipment and people to be conducted on a
chip small enough to fit in the palm of a child`s hand. The chip contains a network of microscopic channels through which fluids
and chemicals are moved in order to perform the experiment. The LabChip® systems are designed to streamline and accelerate
laboratory experimentation and have potential applicability in a broad range of industries including pharmaceuticals, agriculture,
chemicals and diagnostics. Caliper has established multiple strategic and commercial alliances and has built a leading intellectual
property estate in microfluidic technology.

Note: This news release contains forward-looking statements that involve risks and uncertainties. Caliper has identified these
forward-looking statements by using the words ``plans,`` ``believe,`` ``anticipate,`` ``will,`` ``should,`` ``hopeful,`` and ``goal.`` These
statements include Caliper`s expectations as to its financial performance, its expectations regarding the development and timing of
introduction of additional applications for the Agilent 2100 Bioanalyzer, including the Protein LabChip® kit, its plans and timing to
commercialize new programs such as the AMS 90 and ADP, the transition of current TAP customers to full production screening,
its expectations as to the addition of ADP, TAP and VASC customers, and its expectations concerning the litigation with Aclara.
Actual results may differ materially from Caliper`s beliefs and expectations as a result of numerous risks and uncertainties,
including the risks: that Caliper`s LabChip® systems are new and may not achieve market acceptance; that Caliper and its
customers may encounter technological or other difficulties preventing or delaying the introduction of new products or
enhancements; that Caliper`s customers may not perform under the agreements as Caliper expects; and that patent litigation in
which Caliper is currently involved may prevent Caliper from developing new products or enhancing or marketing current
products. These and other risks related to Caliper are detailed in Caliper`s Annual Report on Form 10-K filed with the SEC dated
March 24, 2000.

LabChip is a registered trademark of Caliper Technologies Corp.

(see attached table)

CALIPER TECHNOLOGIES CORP.
SELECTED FINANCIAL INFORMATION
(In thousands, except per share amounts)

STATEMENTS OF OPERATIONS Three Months Ended Nine Months Ended
September 30, September 30,
2000 1999 2000 1999
Revenue $5,507 $3,414 $13,576 $8,859

Costs and expenses:
Research and development 9,826 4,860 24,322 12,302
General and administrative 2,464 1,400 7,300 3,487
Amortization of deferred stock
compensation 1,020 936 3,663 1,997
Total costs and expenses 13,310 7,196 35,285 17,786

Operating loss (7,803) (3,782) (21,709) (8,927)

Interest income, net 1,870 212 4,528 801

Litigation settlement 12,000 -- 12,000 --

Net income/(loss) before
accounting change 6,067 (3,570) (5,181) (8,126)

Cumulative effect of a change
in accounting principle -- -- (2,294) --

Net income/(loss) $6,067 $(3,570) $(7,475) $(8,126)

Net income/(loss) per share - basic
Net income/(loss) before
accounting change $0.28 $(0.23) $(0.24) $(0.53)
Cumulative effect of a change
in accounting principle -- -- (0.11) --
Net income/(loss) $0.28 $(0.23) $(0.35) $(0.53)

Net income/(loss) per share - diluted
Net income/(loss) before
accounting change $0.25 $(0.23) $(0.24) $(0.53)
Cumulative effect of a change
in accounting principle -- -- (0.11) --
Net income/(loss) $0.25 $(0.23) $(0.35) $(0.53)

Shares used in computing net
income/(loss) per share -
basic 21,971 15,354 21,278 15,217
Shares used in computing net
income/(loss) per share -
diluted 24,281 15,354 21,278 15,217


Note: Net loss per share for the three and nine months ended September 30, 1999 is presented on a pro forma basis. Shares used
in computing net loss per share for the three and nine months ended September 30, 1999 are shown on an as-converted basis.

BALANCE SHEET September 30, December 31,
2000 1999
Cash, cash equivalents and short-term
marketable securities $133,829 $73,292
Other current assets 16,946 2,096
Long-term marketable securities 56,899 26,924
Property and equipment, net 6,416 5,346
Other assets 1,275 1,189

Total assets $215,365 $108,847

Current liabilities $10,738 $7,078
Long-term obligations 4,514 3,906
Stockholders` equity 200,113 97,863

Total liabilities and stockholders` equity $215,365 $108,847

SOURCE: Caliper Technologies Corp.

[Gatsby2]

So ein Drecksmarkt heute. Die neue Parole sollte wohl lauten:
"Sell on good news."
CALP verliert fast 10% nach zwei positiven Analysteneinstufungen
und der Bekanntgabe von 5 neuen Patenten.

Robertson Stevens initiated coverage at "BUY"

http://biz.yahoo.com/c/20001122/i.html?calp

Grunthal & Co. reiterates "Aggressive Buy"

http://www.netcog.com/ArticleView.ASP?articleid=80602

Wednesday November 22, 5:42 am Eastern Time

Caliper says gets five microfluidics patents

MOUNTAIN VIEW, Calif., Nov 22 (Reuters) - Laboratory equipment maker Caliper Technologies Corp. said on Wednesday it
received five new patents covering broad areas of microfluidic technology from the U.S. Patent and Trademark Office.

The potentially revolutionary field of microfluidics allows thousands of drug experiments to be simultaneously performed with tiny
amounts of chemicals and few researchers.

The technology sees fluids, proteins, DNA, RNA and other materials move through channels on small chips.

Shares of Caliper, which went public in December and is based in Mountain View, California, finished down about 9 percent, or $4-1/2, at $43-1/8, on the Nasdaq
Tuesday. The stock has a high of $202 and a low of $22-1/2.

[Gatsby2]

Gericht spricht CALIPER gegen Aclara $35 Mio. zu!!

Wenn ich die Meldung richtig verstanden habe ist das Urteil vom Oktober um ingesamt
$ 17 Mio, davon $ 12 Mio. aufgrund der Zahlung der Anwaelte, vermindert worden.

Ein Riesenerfolg fuer Caliper Technologies, und hoffentlich endlich ein Ende der
Prozessflut.
______________

Wednesday November 22, 8:39 pm Eastern Time

Press Release

SOURCE: Caliper Technologies Corp.

Caliper Announces Court Determines Final Damages
Award in Trade Secret Theft Case

MOUNTAIN VIEW, Calif., Nov. 22 /PRNewswire/ -- Caliper Technologies Corp. (Nasdaq: CALP - news) announced that
today the California Superior Court for Santa Clara County determined the final damages award in Caliper`s lawsuit charging trade
secret misappropriation against Aclara BioSciences (Nasdaq: ACLA - news). In September, Caliper reached a $12 million
settlement agreement with the attorneys who were also defendants in this case. In October, a jury awarded Caliper more than $52
million in damages in this case. In a hearing today, the judge ruled that the total amount of the award will be reduced to reflect the
$12 million settlement. The total will also be reduced by the nearly $5 million the jury awarded for conversion, because the court
concluded that this would constitute a double recovery of damages already awarded to Caliper for trade secret misappropriation.

The court also heard arguments today on Caliper`s request for injunctive relief. A decision on that issue remains pending.

``Today`s ruling on damages was not unexpected and we are pleased with the outcome in this case,`` said Dan Kisner, M.D.,
Caliper`s President and Chief Executive Officer. ``The combination of the final award against Aclara and the previous settlement
totals $47 million in damages and unjust enrichment. We feel that this sizeable award is a just recognition of the harm that was
caused by the misappropriation of our trade secrets.``

Caliper Technologies Corp. is a leader in lab-on-a-chip technology. Caliper designs, manufactures, and commercializes LabChip®
devices and systems that enable experiments that ordinarily require laboratories full of equipment and people to be conducted on a
chip small enough to fit in the palm of a child`s hand. The chip contains a network of microscopic channels through which fluids
and chemicals are moved in order to perform the experiment. The LabChip® systems are designed to streamline and accelerate
laboratory experimentation and has potential applicability in a broad range of industries including pharmaceuticals, agriculture,
chemicals and diagnostics. Caliper has established multiple strategic and commercial alliances and has built a leading intellectual
property estate in microfluidic technology.

The foregoing discussion of the jury award and the court`s ruling in Caliper`s trade secret misappropriation case against Aclara
involves risks and uncertainty, including the risks: that Aclara may appeal the verdict, and, if they are successful, the verdict could
be overturned, and that an appeal process could be lengthy and require additional expense. The statements regarding the timing of
future legal proceedings are forward-looking statements that involve risks and uncertainties, including the risks that these
proceedings may be postponed for a variety of reasons, including the filing of additional motions by Caliper or Aclara. These and
other risks related to Caliper are detailed in Caliper`s Annual Report on Form 10-K filed with the SEC dated March 24, 2000, and
in Caliper`s quarterly reports on Form 10-Q as filed with the SEC.

NOTE: LabChip is a registered trademark of Caliper Technologies Corp.

SOURCE: Caliper Technologies Corp.